Berry Street and Healthify Merge to Scale GLP-1 Nutrition Care
Berry Street and Healthify merge to scale AI and clinician-led GLP-1 nutrition care as U.S. drug use is forecast to reach more than 30 million people by 2030.
Summary
On Monday, August 24, 2026, U.S. nutrition startup Berry Street merged with Khosla Ventures-backed Indian startup Healthify, with financial terms undisclosed. Founders Noah Kotlove and Tushar Vashisht will serve as co-CEOs. The combined company will use Berry Street in the U.S. and Healthify in India and other markets, targeting rising demand for GLP-1 weight-loss drugs. A 2026 JP Morgan forecast puts U.S. GLP-1 use above 30 million people by 2030.
Healthify offers app-based AI and human fitness and nutrition coaching, has raised more than $150 million and claims over 45 million customers. It expanded into the U.S. and introduced GLP-1-assisted programs in India in 2025. Berry Street operates more than 2,000 clinics, provides insurance-covered GLP-1 care and raised $50 million from Northzone, Sofina and FJ Labs in 2025. Its AI nutrition coaching and meal tracking have reached a claimed 200,000 people through Amazon, Walmart and other platforms. Healthify says Berry Street adds the clinical and insurance infrastructure needed to scale its AI-led service in the U.S.; Khosla Ventures founder Vinod Khosla says combining AI with nationwide clinicians could expand daily nutrition guidance and dietitian access.
Positives
- More than 2,000 Berry Street clinics give the combined business a nationwide clinical network for insurance-covered GLP-1 care.
- Over 45 million claimed Healthify customers provide a large base for scaling AI and human nutrition coaching.
- More than $150 million raised by Healthify supports a business already operating in India and the U.S.
- A $50 million Berry Street round from Northzone, Sofina and FJ Labs strengthened its funding in 2025.
- Amazon and Walmart collaborations helped Berry Street serve a claimed 200,000 people through AI coaching and meal tracking.
- More than 30 million Americans could use GLP-1 drugs by 2030, according to JP Morgan's 2026 forecast.
Risks & concerns
- Financial terms, including the combined company's valuation and ownership structure, were not disclosed.
- Healthify's 45 million customers and Berry Street's 200,000 users are company-reported figures.
- The 30 million U.S. GLP-1 user estimate is a 2030 forecast rather than current adoption.
- Details remain limited on integration timing, workforce effects and how the co-CEO structure will operate.
- No clinical outcome data were provided for either company's AI coaching or GLP-1 programs.